UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  January 3, 2011
 
Senesco Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
001-31326
84-1368850
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

303 George Street, Suite 420, New Brunswick, New Jersey
08901
(Address of Principal Executive Offices)
(Zip Code)

(732) 296-8400
(Registrant's telephone number,
including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
 
 
 
 
 
Item 8.01 Other Events.
 
On January 3, 2011, Senesco Technologies, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has granted orphan drug designation for the Company’s lead drug candidate, SNS01-T, for treatment of multiple myeloma. As a result, the Company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval, allowance for marketing exclusivity after drug approval for a period of as long as seven years and potential exemption from the FDA’s prescription drug application fee.

On January 3, 2011, the Company issued a press release announcing the grant of orphan drug designation for SNS01-T for treatment of multiple myeloma. A copy of this press release is attached hereto as Exhibit 99.1.
  
Item 9.01.   Financial Statements and Exhibits.
 
  
(d)
Exhibits.
    
Exhibit No. 
  
Description
     
 99.1
  
Press Release of Senesco Technologies, Inc. dated January 3, 2011.
 
 
-2-
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
 
SENESCO TECHNOLOGIES, INC.
  
       
Dated: January 3, 2011
By:
/s/ Leslie J. Browne, Ph.D.  
  Name:    Leslie J. Browne, Ph.D.  
  Title: President and Chief Executive Officer